Abstract | STUDY DESIGN: Meta-analysis of randomized controlled trials (RCTs). OBJECTIVES: METHODS: RESULTS: Three RCTs (5274 patients) were included. Denosumab was not significantly superior to ZA in reducing the likelihood of spinal cord compression, when all tumor types were combined (odds ratio [OR] 0.92, 95% confidence interval [CI; 0.66, 1.28], P = .66). Denosumab was not significantly favored over ZA in endodermal origin (breast and prostate; OR 0.72, 95% CI [0.43, 1.19], P = .20) and mesodermal origin tumors (solid tumors and multiple myeloma; OR 1.10, 95% CI [0.72, 1.69], P = .66). CONCLUSION:
|
Authors | Humaid Al Farii, Abbey Frazer, Leila Farahdel, Saud Alfayez, Michael Weber |
Journal | Global spine journal
(Global Spine J)
Vol. 10
Issue 6
Pg. 784-789
(Sep 2020)
ISSN: 2192-5682 [Print] England |
PMID | 32707021
(Publication Type: Journal Article)
|